Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases [2] - The company's pipeline includes budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody [2] Upcoming Event - Members of Climb Bio's executive team will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025 [1] - The presentation is scheduled for February 12, 2025, at 9:20 a.m. ET [2]